Get startedLog in
    Picture of Bioatla logo

    BCAB — Bioatla News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMicro CapNeutral
    All News

    Brief: BioAtla Updates FDA on Ozuriftamab Vedotin Plan for OPSCC After Positive Phase 2 Results

    Picture of Bioatla logoBioatla
    08/09/2025 13:02
    Sept 8 (Reuters) - Bioatla Inc BCAB.O:

BIOATLA ANNOUNCES REGULATORY UPDATE ON CLINICAL DEVELOPMENT PLAN FOR OZURIFTAMAB VEDOTIN IN OROPHARYNGEAL SQUAMOUS CELL CARCINOMA (OPSCC) FOLLOWING PRODUCTIVE TYPE B (END OF PHASE 2) MEETING WITH FDA

Source text: ID:nGNX4yj9M3

Further company coverage: BCAB.O

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Bioatla

    See all news